^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    α2 adrenergic receptor antagonist

    Related drugs:
    16d
    A Study of Idazoxan in Healthy Participants (clinicaltrials.gov)
    P1, N=150, Active, not recruiting, Terran Biosciences Australia Pty Ltd | Recruiting --> Active, not recruiting | Trial completion date: Mar 2024 --> Dec 2027 | Trial primary completion date: Mar 2024 --> Dec 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    21d
    VEGA-3: Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia (clinicaltrials.gov)
    P3, N=569, Completed, Ocuphire Pharma, Inc. | Trial completion date: May 2026 --> Jan 2026 | Trial primary completion date: Oct 2025 --> Apr 2025 | Active, not recruiting --> Completed
    Trial completion • Trial completion date • Trial primary completion date
    22d
    LYNX-2: Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances (clinicaltrials.gov)
    P3, N=200, Completed, Ocuphire Pharma, Inc. | Active, not recruiting --> Completed
    Trial completion
    2ms
    Effects of Mirtazapine on Appetite in Advanced Cancer Patients (clinicaltrials.gov)
    P2, N=98, Active, not recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial primary completion date
    2ms
    Mirtazapine for Acute and Chronic Post Mastectomy Pain (clinicaltrials.gov)
    P1, N=62, Completed, Assiut University | Active, not recruiting --> Completed | Trial completion date: Dec 2027 --> Dec 2025 | Trial primary completion date: Jul 2027 --> Dec 2025
    Trial completion • Trial completion date • Trial primary completion date
    3ms
    Effects of Mirtazapine on Appetite in Advanced Cancer Patients (clinicaltrials.gov)
    P2, N=98, Active, not recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Dec 2027 --> Dec 2025
    Trial primary completion date
    3ms
    A Study to Assess the Safety and Efficacy of Centhaquine in Hypovolemic Shock Patients (clinicaltrials.gov)
    P4, N=400, Recruiting, Pharmazz, Inc. | Trial completion date: Dec 2025 --> Aug 2026 | Trial primary completion date: Nov 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    3ms
    A Study to Assess Safety and Efficacy of Centhaquine as a Resuscitative Agent (clinicaltrials.gov)
    P3, N=430, Not yet recruiting, Pharmazz, Inc. | Trial completion date: Oct 2026 --> Oct 2027
    Trial completion date
    3ms
    Effects of Mirtazapine on Appetite in Advanced Cancer Patients (clinicaltrials.gov)
    P2, N=98, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    3ms
    Novel Pilot Study to Treat Symptoms of IBS With Diarrhea Using Combination Therapy of a Low-FODMAP Diet and a Neuromodulator (clinicaltrials.gov)
    P1, N=20, Recruiting, Mayo Clinic | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    5ms
    O-GlcNAcylation of SPOP regulates colorectal cancer progression and ferroptosis by mediating β-catenin degradation. (PubMed, Cell Death Discov)
    Combined treatment with the SPOP-targeted drug maprotiline and a ferroptosis inducer has synergistic antitumor efficacy in CRC cells and xenografts. Our study reveals the multifaceted function of SPOP in CRC, and the activation of SPOP may be a feasible strategy to increase the sensitivity of CRC to ferroptosis inducers.
    Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1) • SPOP (Speckle Type BTB/POZ Protein) • SLC7A11 (Solute Carrier Family 7 Member 11)
    |
    maprotiline
    5ms
    Multicentric, Randomized Study to Assess Safety and Efficacy of Centhaquine in Patients With ARDS (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Pharmazz, Inc. | N=60 --> 80 | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Oct 2025 --> Oct 2026
    Enrollment change • Trial completion date • Trial primary completion date